David Kreling, professor emeritus in the School of Pharmacy at the University of Wisconsin-Madison, said the U.S. price quoted by Baldwin sounds about right.
“The $500 number may be in the ballpark for U.S. patented (brand-name, newer) drugs,” Kreling said in an email to PolitiFact Wisconsin. “That would be consistent with my understanding of market data on sales by firms in the U.S. Things in the $7 range, here, only reside within the off-patent generic drug market (where we have low prices, sometimes at or near lowest in the world).”